List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4112826/publications.pdf Version: 2024-02-01



STEEAN I TEIDEI

#	Article	IF	CITATIONS
1	The patients' and caregivers' perspective: In-hospital navigation aids for people with dementia- a qualitative study with a value sensitive design approach. Assistive Technology, 2023, 35, 248-257.	2.0	5
2	Microvascular Breakdown Due to Retinal Neurodegeneration in Ataxias. Movement Disorders, 2022, 37, 162-170.	3.9	6
3	Stakeholder involvement in dementia research: A qualitative approach with healthy senior citizens and providers of dementia care in Germany. Health and Social Care in the Community, 2022, 30, 908-917.	1.6	8
4	Loss of "insight―into behavioral changes in ALS: Differences across cognitive profiles. Brain and Behavior, 2022, 12, e2439.	2.2	3
5	Reply to: "Microvascular Breakdown Due to Retinal Neurodegeneration in Ataxias― Movement Disorders, 2022, 37, 438-438.	3.9	1
6	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	2.8	14
7	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. Neuron, 2022, 110, 1009-1022.e4.	8.1	27
8	Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-16.	2.6	3
9	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2022, 85, 1267-1282.	2.6	12
10	Antemortem basal forebrain atrophy in pure limbic TAR DNAâ€binding protein 43 pathology compared with pure Alzheimer pathology. European Journal of Neurology, 2022, 29, 1394-1401.	3.3	3
11	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. Journal of Nuclear Medicine, 2022, 63, 981-985.	5.0	9
12	A Bayesian perspective on Biogen's aducanumab trial. Alzheimer's and Dementia, 2022, 18, 2341-2351.	0.8	5
13	Prediction of Disorientation by Accelerometric and Gait Features in Young and Older Adults Navigating in a Virtually Enriched Environment. Frontiers in Psychology, 2022, 13, 882446.	2.1	0
14	Matching values to technology: a value sensitive design approach to identify values and use cases of an assistive system for people with dementia in institutional care. Ethics and Information Technology, 2022, 24, .	3.8	2
15	An algorithm for actigraphy-based sleep/wake scoring: Comparison with polysomnography. Clinical Neurophysiology, 2021, 132, 137-145.	1.5	21
16	Association of TDP-43 Pathology with Global and Regional 18F-Florbetapir PET Signal in the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2021, 79, 663-670.	2.6	4
17	Association of PETâ€based stages of amyloid deposition with neuropathological markers of Aβ pathology. Annals of Clinical and Translational Neurology, 2021, 8, 29-42.	3.7	7
18	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. NeuroImage: Clinical, 2021, 29, 102533.	2.7	15

#	Article	IF	CITATIONS
19	Structural MRI of the basal forebrain as predictor of cognitive response to galantamine in healthy older adults—A randomized controlled doubleâ€blinded crossover study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12153.	3.7	4
20	Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration. Alzheimer's Research and Therapy, 2021, 13, 49.	6.2	44
21	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	6.4	18
22	Long-Term Caloric Restriction Attenuates β-Amyloid Neuropathology and Is Accompanied by Autophagy in APPswe/PS1delta9 Mice. Nutrients, 2021, 13, 985.	4.1	15
23	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.8	64
24	Neuronal Hyperexcitability in APPSWE/PS1dE9 Mouse Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 81, 855-869.	2.6	14
25	How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 917-919.	0.8	5
26	Case Report: Cognitive Conversion in a Non-brazilian VAPB Mutation Carrier (ALS8). Frontiers in Neurology, 2021, 12, 668772.	2.4	4
27	Cognitive reserve and regional brain volume in amyotrophic lateral sclerosis. Cortex, 2021, 139, 240-248.	2.4	13
28	Improving the depth of data quality or increasing confusion? Reflections on a data analysis involving members of a selfâ€help group for relatives of people living with dementia. Health Expectations, 2021, 24, 1516-1523.	2.6	7
29	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. Neurobiology of Aging, 2021, 103, 78-97.	3.1	9
30	Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. Journal of Affective Disorders, 2021, 293, 429-434.	4.1	5
31	Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69.	3.1	5
32	In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 178.	6.2	6
33	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 191.	6.2	21
34	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. Frontiers in Aging Neuroscience, 2021, 13, 748198.	3.4	3
35	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. Alzheimer's and Dementia, 2021, 17, .	0.8	1
36	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	1

#	Article	IF	CITATIONS
37	Restingâ \in state functional connectivity of basal forebrain is associated with training gains in normal aging. Alzheimer's and Dementia, 2021, 17, .	0.8	0
38	Association between SCDâ€Plus features and GDS factors in subjective cognitive decline and healthy controls in the studies DELCODE and SILCODE. Alzheimer's and Dementia, 2021, 17, .	0.8	0
39	Cost of illness of apathy in Alzheimer $\hat{a} \in \mathbb{M}$ s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
40	Characterization of the NIAâ€AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
41	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
42	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimer's disease: The first step towards comprehensive artificial intelligence. Alzheimer's and Dementia, 2021, 17, .	0.8	0
43	Prediction of amyloidâ€positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize numberâ€neededâ€toâ€screen. Alzheimer's and Dementia, 2021, 17, .	0.8	0
44	Monitoring physical parameters from wearable sensors for detection of cognitive decline in routine care. Alzheimer's and Dementia, 2021, 17, .	0.8	0
45	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	3.1	150
46	Real-Time Detection of Spatial Disorientation in Persons with Mild Cognitive Impairment and Dementia. Gerontology, 2020, 66, 85-94.	2.8	21
47	Automated sensorâ€based detection of challenging behaviors in advanced stages of dementia in nursing homes. Alzheimer's and Dementia, 2020, 16, 672-680.	0.8	12
48	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.1	20
49	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59.	3.1	30
50	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. NeuroImage: Clinical, 2020, 28, 102495.	2.7	17
51	Disentangling neurodegeneration subtypes of Alzheimer's disease using dataâ€driven methods. Alzheimer's and Dementia, 2020, 16, e037183.	0.8	0
52	Deep learning models for generating diagnostic explanations. Alzheimer's and Dementia, 2020, 16, e037353.	0.8	0
53	Validation of convolutional neural network relevance maps for revealing patterns of Alzheimer's disease in MRI scans. Alzheimer's and Dementia, 2020, 16, e037967.	0.8	0
54	Useâ€cases and users' requirements for design of an individualized sensorâ€based assistive system for people with dementia in nursing facilities: A user centered design approach using qualitative research. Alzheimer's and Dementia, 2020, 16, e038251.	0.8	0

#	Article	IF	CITATIONS
55	What can lipidomics tell about pathoâ€mechanisms at the early phases of Alzheimer's disease?. Alzheimer's and Dementia, 2020, 16, e038950.	0.8	0
56	Sensorâ€based activity and state recognition in dementia patients in stationary care as basis for situationâ€aware assistive devices. Alzheimer's and Dementia, 2020, 16, e038989.	0.8	0
57	Stakeholder engagement in dementia care research: Identification of stakeholders and their perspectives on participatory research. Alzheimer's and Dementia, 2020, 16, e039666.	0.8	0
58	†No, I don't know where that is. All I know is my room.': Topographical disorientation and userâ€centred requirements for inâ€hospital navigation aids of people with dementia and their caregivers. Alzheimer's and Dementia, 2020, 16, e039686.	0.8	0
59	In vivo amyloid progression in healthy middleâ€aged to older people at risk of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040789.	0.8	0
60	FDGâ€₽ET subtypes of Alzheimer's disease and their association with distinct biomarker profiles and clinical trajectories. Alzheimer's and Dementia, 2020, 16, e042101.	0.8	3
61	Protocol of a cluster randomised controlled trial to assess the effectiveness of a care management programme for caregivers of people with dementia (GAP study). Alzheimer's and Dementia, 2020, 16, e043879.	0.8	0
62	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSFâ€ADâ€pathology: Data from the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e044741.	0.8	1
63	Awareness of cognitive decline and CSFâ€biomarkers in memory clinic patients: Results from the DELCODEâ€study. Alzheimer's and Dementia, 2020, 16, e044744.	0.8	0
64	The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2020, 16, e045349.	0.8	0
65	Gaussian Graphical Models Reveal Inter-Modal and Inter-Regional Conditional Dependencies of Brain Alterations in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 99.	3.4	31
66	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. Brain Research Bulletin, 2020, 161, 13-20.	3.0	3
67	Cognitive Reserve Is Not Associated With Hippocampal Microstructure in Older Adults Without Dementia. Frontiers in Aging Neuroscience, 2020, 11, 380.	3.4	3
68	InÂvivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. Neurobiology of Aging, 2020, 93, 98-108.	3.1	21
69	Mirror Movements in Amyotrophic Lateral Sclerosis: A Combined Study Using Diffusion Tensor Imaging and Transcranial Magnetic Stimulation. Frontiers in Neurology, 2020, 11, 164.	2.4	6
70	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.1	58
71	Longitudinal validity of <scp>PET</scp> â€based staging of regional amyloid deposition. Human Brain Mapping, 2020, 41, 4219-4231.	3.6	25
72	Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. Neurology, 2020, 95, e1301-e1311.	1.1	29

#	Article	IF	CITATIONS
73	Cholinergic white matter pathways make a stronger contribution to attention and memory in normal aging than cerebrovascular health and nucleus basalis of Meynert. NeuroImage, 2020, 211, 116607.	4.2	59
74	Effect of Spatial Disorientation in a Virtual Environment on Gait and Vital Features in Patients with Dementia: Pilot Single-Blind Randomized Control Trial. JMIR Serious Games, 2020, 8, e18455.	3.1	5
75	Measuring motion behavior to detect spatial disorientation in a VR environment. , 2020, , .		0
76	Technology for mobility: A user-centered approach evaluating affinity for technology and requirements for a navigation assistant for people with cognitive impairment. Gerontechnology, 2020, 20, 1-13.	0.1	1
77	Development of a digital system to assess and manage unmet needs of family dementia caregivers in clinical practice. Alzheimer's and Dementia, 2020, 16, e043142.	0.8	0
78	Cholinergic network disruption in AD subtypes: A study using graph theory. Alzheimer's and Dementia, 2020, 16, e043178.	0.8	0
79	Costâ€effectiveness of a collaborative dementia care management—Results of a clusterâ€randomized controlled trial. Alzheimer's and Dementia, 2019, 15, 1296-1308.	0.8	49
80	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53.	3.1	48
81	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465.	2.6	15
82	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease based on multicenter diffusion tensor imaging. Journal of Neurology, 2019, 266, 2465-2474.	3.6	35
83	The effects of 7â€week cognitive training in patients with vascular cognitive impairment, no dementia (the Cogâ€VACCINE study): A randomized controlled trial. Alzheimer's and Dementia, 2019, 15, 605-614.	0.8	47
84	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer's Research and Therapy, 2019, 11, 15.	6.2	24
85	F4â€03â€01: NEUROPATHOLOGICAL FEATURES UNDERLYING ANTEâ€MORTEM CHOLINERGIC BASAL FOREBRAIN MEDIAL TEMPORAL LOBE ATROPHY IN THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2019, 15, P1220.	I AND 0.8	0
86	ICâ€Pâ€122: ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT I STAGES OF ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2019, 15, P101.	RISK 0.8	0
87	ICâ€Pâ€069: LONGITUDINAL ANALYSIS OF THE STRUCTURAL AND COGNITIVE PHENOTYPE OF AMYLOID POSITIVE AND NEGATIVE PARKINSON'S DISEASE PATIENTS. Alzheimer's and Dementia, 2019, 15, P64.	E _{0.8}	0
88	ICâ€Pâ€028: PATTERNS OF INCREASED AND DECREASED PRECUNEUS FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS. Alzheimer's and Dementia, 2019, 15, P35.	0.8	0
89	ICâ€04â€01: THE SEARCH FOR PATHOLOGICALLY VALID IMAGING BIOMARKERS: AD PATHOLOGY COMES NOT ALONE. Alzheimer's and Dementia, 2019, 15, P4.	0.8	0
90	ICâ€Pâ€010: INâ€VIVO MODELS OF REGIONAL AMYLOID STAGING: LONGITUDINAL VALIDITY AND IMPACT OF REGIONâ€SPECIFIC THRESHOLDS. Alzheimer's and Dementia, 2019, 15, P19.	0.8	0

#	Article	IF	CITATIONS
91	ICâ€Pâ€016: CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCL BASALIS MEYNERT IN AMYLOIDâ€POSITIVE SCD. Alzheimer's and Dementia, 2019, 15, P25.	EUS 0.8	0
92	ICâ€₽â€020: INVESTIGATING THE PROGRESSION OF NEUROIMAGING BIOMARKERS IN THE APPSWE/PS1DE9 TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P28.	0.8	0
93	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. Radiology, 2019, 290, 167-176.	7.3	30
94	The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles. Human Brain Mapping, 2019, 40, 868-878.	3.6	47
95	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.8	28
96	Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD). NeuroImage: Clinical, 2019, 21, 101612.	2.7	35
97	A Tablet App– and Sensor-Based Assistive Technology Intervention for Informal Caregivers to Manage the Challenging Behavior of People With Dementia (the insideDEM Study): Protocol for a Feasibility Study. JMIR Research Protocols, 2019, 8, e11630.	1.0	8
98	Cholinergic forebrain density loss in Parkinson disease. Neurology, 2018, 90, 823-824.	1.1	3
99	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	6.2	131
100	Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia. Current Geriatrics Reports, 2018, 7, 1-11.	1.1	75
101	Alzheimer's disease biomarkerâ€guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Al² _{1–42} , totalâ€ŧau, phosphorylatedâ€ŧau, NFL, neurogranin, and YKLâ€40. Alzheimer's and Dementia, 2018, 14, 492-501.	0.8	91
102	In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. Brain, 2018, 141, 165-176.	7.6	135
103	Mean diffusivity in cortical gray matter in Alzheimer's disease: The importance of partial volume correction. NeuroImage: Clinical, 2018, 17, 579-586.	2.7	40
104	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. NeuroImage: Clinical, 2018, 17, 435-443.	2.7	19
105	Comparison of Different Hypotheses Regarding the Spread of Alzheimer's Disease Using Markov Random Fields and Multimodal Imaging. Journal of Alzheimer's Disease, 2018, 65, 731-746.	2.6	6
106	P1â€379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443.	0.8	0
107	P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VA OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ _{1â€42} , TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154.	LUE 0.8	1
108	P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206.	0.8	0

#	Article	IF	CITATIONS
109	P2â€434: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P879.	0.8	0
110	P2â€455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.8	0
111	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.8	0
112	P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES C ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228.	OF 0.8	0
113	P3â€411: CLINICAL SIGNIFICANCE OF INâ€VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P1262.	0.8	0
114	ICâ€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.8	0
115	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.8	8
116	P4â€165: COSTâ€UTILITY ANALYSIS OF DEMENTIA CARE MANAGEMENT: RESULTS OF THE CLUSTERâ€RANDOMIZ CONTROLLED, INTERVENTIONAL TRIAL DELPHIâ€MV. Alzheimer's and Dementia, 2018, 14, P1502.	ZED. 0.8	0
117	ICâ€₽â€163: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P137.	0.8	0
118	F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396.	0.8	0
119	F1â€04â€03: EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P207.	0.8	0
120	P2â€447: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P888.	0.8	0
121	O4â€07â€04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. Alzheimer's and Dementia, 2018, 14, P1419.	0.8	0
122	F1â€05â€02: INSIDEDEM: TECHNOLOGY FOR MANAGING CHALLENGING BEHAVIOR IN DEMENTIA. Alzheimer's ar Dementia, 2018, 14, P209.	nd 0.8	0
123	6 .Diagnostische Methoden. , 2018, , 187-352.		0
124	P2â€397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN. Alzheimer's and Dementia, 2018, 14, P855.	0.8	0
125	P2â€288: MEASURING GAIT CHARACTERISTICS OF INDUCED DISORIENTATION IN A VR ENVIRONMENT. Alzheimer's and Dementia, 2018, 14, P791.	0.8	0
126	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. Frontiers in Neurology, 2018, 9, 642.	2.4	32

#	Article	IF	CITATIONS
127	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHTâ€preAD study. Alzheimer's and Dementia, 2018, 14, 1126-1136.	0.8	20
128	Use of nonintrusive sensorâ€based information and communication technology for realâ€world evidence for clinical trials in dementia. Alzheimer's and Dementia, 2018, 14, 1216-1231.	0.8	55
129	Prevalence and Determinants of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients Screened Positive for Dementia: Results from the Population-Based DelpHi-Study. Journal of Alzheimer's Disease, 2018, 64, 1091-1097.	2.6	5
130	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's and Dementia, 2018, 14, 1204-1215.	0.8	79
131	Mechanisms and modulators of cognitive training gain transfer in cognitively healthy aging: study protocol of the AgeGain study. Trials, 2018, 19, 337.	1.6	9
132	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 801-813.	2.6	19
133	In Vivo Volumetry of the Cholinergic Basal Forebrain. Neuromethods, 2018, , 213-232.	0.3	5
134	Parallel Atrophy of Cortex and Basal Forebrain Cholinergic System in Mild Cognitive Impairment. Cerebral Cortex, 2017, 27, bhw019.	2.9	32
135	The European DTI Study on Dementia — A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. NeuroImage, 2017, 144, 305-308.	4.2	33
136	Twoâ€level diagnostic classification using cerebrospinal fluid YKLâ€40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003.	0.8	39
137	Multicenter stability of resting state fMRI in the detection of Alzheimer's disease and amnestic MCI. NeuroImage: Clinical, 2017, 14, 183-194.	2.7	49
138	Translation of imaging biomarkers from clinical research to healthcare. Zeitschrift Fur Gerontologie Und Geriatrie, 2017, 50, 84-88.	1.8	3
139	Multidimensional assessment of challenging behaviors in advanced stages of dementia in nursing homes—The insideDEM framework. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 36-44.	2.4	18
140	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. Neurochemistry International, 2017, 108, 355-360.	3.8	46
141	On the applicability of clinical observation tools for human activity annotation. , 2017, , .		7
142	Disrupted white matter structural networks in healthy older adult APOE ε4 carriers – An international multicenter DTI study. Neuroscience, 2017, 357, 119-133.	2.3	31
143	Basal forebrain mediated increase in brain CRF is associated with increased cholinergic tone and depression. Psychiatry Research - Neuroimaging, 2017, 264, 76-81.	1.8	0
144	Cognitive reserve moderates the association between functional network anti-correlations and memory in MCI. Neurobiology of Aging, 2017, 50, 152-162.	3.1	63

#	Article	IF	CITATIONS
145	PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET – Application to amyloid imaging with AV45-PET. NeuroImage, 2017, 147, 669-677.	4.2	134
146	Reduced Cholinergic Basal Forebrain Integrity Links Neonatal Complications and Adult Cognitive Deficits After Premature Birth. Biological Psychiatry, 2017, 82, 119-126.	1.3	30
147	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334.	2.6	35
148	In vivo staging of regional amyloid deposition. Neurology, 2017, 89, 2031-2038.	1.1	321
149	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. Scientific Reports, 2017, 7, 11706.	3.3	79
150	[P3–395]: USING NEUROMELANINâ€SENSITIVE MRI TO CHARACTERISE THE STRUCTURAL INTEGRITY OF THE HUMAN LOCUS COERULEUS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1114.	0.8	0
151	[P2–074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. Alzheimer's and Dementia, 2017, 13, P634.	0.8	Ο
152	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	10.2	464
153	APPswe/PS1dE9 mice with cortical amyloid pathology show a reduced NAA/Cr ratio without apparent brain atrophy: A MRS and MRI study. NeuroImage: Clinical, 2017, 15, 581-586.	2.7	16
154	[ICâ€Pâ€080]: USEFULNESS AND STABILITY OF MULTICENTER DIFFUSION TENSOR IMAGING AS AN EARLY MARKE FOR SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: FIRST RESULTS FROM THE PROSPECTIVE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P66.	ER 0.8	2
155	[P2–370]: REGIONAL AMYLOID DEPOSITS DO NOT IMPAIR NEURONAL FUNCTION IN A COGNITIONâ€RELEVAN MANNER. Alzheimer's and Dementia, 2017, 13, P767.	^Т о.8	Ο
156	[P2–390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. Alzheimer's and Dementia, 2017, 13, P779.	0.8	1
157	[P2–412]: A FUNCTIONAL RESTING STATE STUDY OF BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN ASYMPTOMATIC ATâ€RISK INDIVIDUALS FOR AD: THE INSIGHTâ€PREAD STUDY. Alzheimer's and Dementia, 2017, 13, P790.	0.8	0
158	[P2–550]: CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSFâ€TAU MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P854.	ON 0.8	0
159	[P3–218]: TAU PLASMA LEVELS IN SUBJECTIVE COGNITIVE DECLINE: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1021.	0.8	1
160	[P3–350]: GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS. Alzheimer's and Dementia, 2017, 13, P1089.	0.8	0
161	[P3–372]: DOMAINâ€5PECIFIC MNEMONIC DISCRIMINATION IN AGEING AND EARLY STAGES OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1100.	0.8	0
162	[P3–387]: HIPPOCAMPAL MEAN DIFFUSIVITY FOR THE DIAGNOSIS OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT IN A PRIMARY CARE SAMPLE. Alzheimer's and Dementia, 2017, 13, P1108.	0.8	0

#	Article	IF	CITATIONS
163	[P3–393]: ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER'S DISEASE BASED ON MULTICENTER RESTING‧TATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1112.	0.8	0
164	[P1–122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER's DISEASE, AND NEURAL NETWORKS. Alzheimer's and Dementia, 2017, 13, P287.	0.8	2
165	[P4–206]: DIAGNOSTIC AND PREDICTIVE POTENTIALS OF HIPPOCAMPUS VOLUMETRY IN PRIMARY CARE AND SPECIALIZED CARE SETTINGS. Alzheimer's and Dementia, 2017, 13, P1345.	0.8	0
166	[P4–248]: QUALITY ASSURANCE IN DELCODE: A MULTI ENTER NEUROIMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P1372.	0.8	0
167	[P4–325]: USING VIDEO ANNOTATION TO DETECT CHALLENGING BEHAVIORS IN PEOPLE IN ADVANCED STAGE OF DEMENTIA: THE INSIDEDEM STUDY. Alzheimer's and Dementia, 2017, 13, P1414.	S _{0.8}	0
168	[ICâ€Pâ€029]: GAUSSIAN MARKOV RANDOM FIELDS FOR ASSESSING INTERMODAL REGIONAL ASSOCIATIONS IN PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P26.	0.8	0
169	[ICâ€Pâ€030]: CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSFâ€TAI MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P28.	1 ON 0.8	0
170	[ICâ€Pâ€071]: HETEROGENEITY OF HYPOMETABOLIC BRAIN DYSFUNCTION IN AMNESTIC MCI: A HIERARCHICAL CLUSTERING APPROACH BASED ON BRAINâ€WIDE METABOLIC PROFILES. Alzheimer's and Dementia, 2017, 13, P59.	0.8	0
171	[ICâ€Pâ€086]: NEURONAL CORRELATES OF DELAYED RECALL TEST PERFORMANCE IN MILD COGNITIVE IMPAIRMENT: BEYOND CONVENTIONAL LINEAR REGRESSION. Alzheimer's and Dementia, 2017, 13, P69.	0.8	0
172	[ICâ€Pâ€118]: GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJEC Alzheimer's and Dementia, 2017, 13, P91.	CTS. 0.8	0
173	[ICâ€Pâ€152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€STATE EEG FUNCTIONAL CONNECT IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€PRE AD STUDY. Alzheimer's and Dementia, 2017, 13, P114.	IVITY 0.8	0
174	[ICâ€Pâ€161]: MEAN DIFFUSIVITY IN CORTICAL GRAY MATTER IN ALZHEIMER's DISEASE: THE IMPORTANCE OF PARTIAL VOLUME CORRECTION. Alzheimer's and Dementia, 2017, 13, P123.	0.8	0
175	[P1–441]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€STATE EEG FUNCTIONAL CONNECTIVI IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€PREâ€AD STUDY. Alzheimer's and Dementia, 2017, 13, P451.	TY 0.8	0
176	[P1–592]: COST OF DIAGNOSING DEMENTIA IN A GERMAN MEMORY CLINIC. Alzheimer's and Dementia, 2017, 13, P522.	0.8	0
177	[P3–482]: DRUG INTERACTIONS IN COMMUNITYâ€DWELLING PEOPLE SCREENED POSITIVE FOR DEMENTIA: RESULTS OF THE DELPHI STUDY. Alzheimer's and Dementia, 2017, 13, P1161.	0.8	0
178	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Alzheimer's Research and Therapy, 2017, 9, 84.	6.2	58
179	Potential Role of Neuroimaging Markers for Early Diagnosis of Dementia in Primary Care. Current Alzheimer Research, 2017, 15, 18-27.	1.4	18
180	White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. Frontiers in Aging Neuroscience, 2017, 9, 47.	3.4	46

#	Article	IF	CITATIONS
181	Cost of diagnosing dementia in a German memory clinic. Alzheimer's Research and Therapy, 2017, 9, 65.	6.2	14
182	Situation Model for Situation-Aware Assistance of Dementia Patients in Outdoor Mobility. Journal of Alzheimer's Disease, 2017, 60, 1461-1476.	2.6	16
183	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. Neurobiology of Aging, 2017, 57, 143-152.	3.1	18
184	Contribution of the Cholinergic System toÂVerbal Memory Performance in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 53, 991-1001.	2.6	26
185	Association Between Smoking and Cholinergic Basal Forebrain Volume in Healthy Aging and Prodromal and Dementia Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 52, 1443-1451.	2.6	13
186	The Primacy Effect in Amnestic Mild Cognitive Impairment: Associations with Hippocampal Functional Connectivity. Frontiers in Aging Neuroscience, 2016, 8, 244.	3.4	18
187	TDâ€Pâ€019: Sensing Disorientation of Persons with Dementia in Outdoor Wayfinding Tasks Using Wearable Sensors to Enable Situationâ€Aware Navigation Assistance. Alzheimer's and Dementia, 2016, 12, P160.	0.8	2
188	P1-215: Behavioural Manifestations of Disorientation of Persons with Alzheimer's Disease Dementia in Outdoor Wayfinding Tasks: Towards a Situation Aware Assistance. , 2016, 12, P488-P488.		3
189	P4â€221: White Matter Damage in Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment No Dementia. Alzheimer's and Dementia, 2016, 12, P1113.	0.8	0
190	IC-P-045: Functional Connectivity in Alzheimer's Dementia and Mild Cognitive Impairment: A Large-Scale Multicenter Resting-State FMRI Study. , 2016, 12, P38-P38.		0
191	IC-P-035: Association of Hippocampal Resting State Networks and The Primacy Effect as A Marker of Consolidation in Amnestic MCI. , 2016, 12, P32-P33.		0
192	O2-14-06: Drug-Related Problems in Community-Dwelling Primary Care Patients with Dementia: The Effect of Dementia Care Management. , 2016, 12, P266-P266.		0
193	ICâ€₽â€010: Increased Sensitivity of AV45â€Pet for The Detection of Early Stage Amyloidosis After Correction of White Matter Spillâ€In Effects. Alzheimer's and Dementia, 2016, 12, P19.	0.8	0
194	ICâ€Pâ€037: Simultaneous Eegâ€Fmri in Patients with Alzheimer's Disease: are Bold Signal Fluctuations in The Default Mode Network Correlated with Alpha Band Power?. Alzheimer's and Dementia, 2016, 12, P33.	² 0.8	0
195	IC-P-052: Amyloid Levels in Cerebral Spinal Fluid Influences The Pattern of Cortical and Basal Forebrain Atrophy in Mild Cognitive Impairment. , 2016, 12, P43-P43.		0
196	P1â€316: Simultaneous EEGâ€FMRI in Patients with Alzheimer's Disease: Are Bold Signal Fluctuations in The Default Mode Network Correlated with Alpha Band Power?. Alzheimer's and Dementia, 2016, 12, P544.	0.8	0
197	P1â€446: Psychotherapy Intervention for Family Caregivers: A Systematic Evaluation of Qualitative Outcomes. Alzheimer's and Dementia, 2016, 12, P605.	0.8	0
198	P1â€447: Psychotherapy Intervention for Family Caregivers: Does Early Intervention Matter?. Alzheimer's and Dementia, 2016, 12, P606.	0.8	0

#	Article	IF	CITATIONS
199	P2â€236: Association of Hippocampal Resting State Networks and the Primacy Effect as a Marker of Consolidation in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P714.	0.8	0
200	P3â€281: Altered Functional Connectivity of the Default Mode Network in Alzheimer's Dementia and Mild Cognitive Impairment: Results From a Largeâ€6cale Multicenter Restingâ€6tate Fmri Study. Alzheimer's and Dementia, 2016, 12, P945.	0.8	0
201	F3-04-02: Molecular Properties Underlying Regional Vulnerability Profiles for Amyloid Deposition and Neurodegeneration in Alzheimer's Disease. , 2016, 12, P274-P275.		2
202	P1â€024: Increased Sensitivity of AV45â€PET for the Detection of Early Stage Amyloidosis After Correction of White Matter Spillâ€in Effects. Alzheimer's and Dementia, 2016, 12, P409.	0.8	0
203	Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care?. Journal of Alzheimer's Disease, 2016, 55, 1379-1394.	2.6	11
204	Measuring Cortical Connectivity in Alzheimer's Disease as a Brain Neural Network Pathology: Toward Clinical Applications. Journal of the International Neuropsychological Society, 2016, 22, 138-163.	1.8	92
205	No Change in Executive Performance in ALS Patients: A Longitudinal Neuropsychological Study. Neurodegenerative Diseases, 2016, 16, 184-191.	1.4	35
206	Towards a situation model for assessing challenging behaviour of people with dementia. , 2016, , .		4
207	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	2.4	21
208	Applied multimodal diagnostics in a case of presenile dementia. BMC Neurology, 2016, 16, 131.	1.8	3
209	TDP-43 pathology and cognition in ALS. Neurology, 2016, 87, 1019-1023.	1.1	45
210	Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks. Human Brain Mapping, 2016, 37, 35-53.	3.6	119
211	P2â€250: Reduced White Matter Integrity of the Rostral Limbic System Pathways in Healthy Elderly APOE E4 Allele Carriers. Alzheimer's and Dementia, 2016, 12, P721.	0.8	0
212	F3â€03â€02: Computational Description of Wayfinding Behavior in Outdoor Environments of People with Dementia Using Ontologies and Sensor Data. Alzheimer's and Dementia, 2016, 12, P272.	0.8	4
213	Is the left uncinate fasciculus associated with verbal fluency decline in mild Alzheimer's disease?. Translational Neuroscience, 2016, 7, 89-91.	1.4	7
214	Information and communication technology solutions for outdoor navigation in dementia. Alzheimer's and Dementia, 2016, 12, 695-707.	0.8	80
215	Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study. Psychiatry Research - Neuroimaging, 2016, 249, 84-90.	1.8	10
216	Functional connectivity increase in the default-mode network of patients with Alzheimer× ³ s disease after long-term treatment with Galantamine. European Neuropsychopharmacology, 2016, 26, 602-613.	0.7	23

#	Article	IF	CITATIONS
217	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. Neuropharmacology, 2016, 108, 128-135.	4.1	23
218	Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 526-536.	6.4	58
219	Output order and variability in free recall are linked to cognitive ability and hippocampal volume in elderly individuals. Neuropsychologia, 2016, 80, 126-132.	1.6	9
220	Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. Cerebral Cortex, 2016, 26, 2411-2426.	2.9	81
221	Robust Detection of Impaired Resting State Functional Connectivity Networks in Alzheimer's Disease Using Elastic Net Regularized Regression. Frontiers in Aging Neuroscience, 2016, 8, 318.	3.4	36
222	Neuronal correlates of serial position performance in amnestic mild cognitive impairment Neuropsychology, 2016, 30, 906-914.	1.3	15
223	Hearing Impairment Affects Dementia Incidence. An Analysis Based on Longitudinal Health Claims Data in Germany. PLoS ONE, 2016, 11, e0156876.	2.5	62
224	IC-04-02: The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment: The curse of dimensionality. , 2015, 11, P10-P11.		0
225	P2-131: Analysis of inter-modal associations and dependencies of regional disease patterns based on multimodal imaging using markov random fields. , 2015, 11, P534-P534.		0
226	Rates of formal diagnosis of dementia in primary care: The effect ofÂscreening. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 87-93.	2.4	53
227	P3-146: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: A multicenter DTI and volumetry study. , 2015, 11, P682-P682.		0
228	P3-174: Structural connectivity as a biomarker for Alzheimer's disease: Evaluation in a multicenter trial and a primary care cohort. , 2015, 11, P696-P696.		1
229	P4-086: Is hippocampal size associated with primacy recall performance in amnestic mild cognitive impairment?. , 2015, 11, P805-P805.		0
230	P2-293: Short-term psychotherapy for family caregivers: Evaluation of the pilot study. , 2015, 11, P604-P604.		0
231	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment – A Multicenter DTI and Volumetry Study. Journal of Alzheimer's Disease, 2015, 48, 197-204.	2.6	56
232	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	2.6	34
233	IC-P-127: CSF parameters of neurodestruction and atrophy of the basal forebrain cholinergic system in mild cognitive impairment. , 2015, 11, P86-P87.		0

P2-179: In-vivo staging of preclinical amyloid deposition. , 2015, 11, P560-P561.

0

#	Article	IF	CITATIONS
235	Regional Pattern of Dementia and Prevalence of Hearing Impairment in Germany. Journal of the American Geriatrics Society, 2015, 63, 1527-1533.	2.6	37
236	Antidementia Drug Treatment in People Screened Positive for Dementia in Primary Care. Journal of Alzheimer's Disease, 2015, 44, 1015-1021.	2.6	24
237	Effects of Task-Irrelevant Emotional Stimuli on Working Memory Processes in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 44, 439-453.	2.6	12
238	Structural Connectivity Changes Underlying Altered Working Memory Networks in Mild Cognitive Impairment: A Threeâ€Way Image Fusion Analysis. Journal of Neuroimaging, 2015, 25, 634-642.	2.0	10
239	Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. Journal of Alzheimer's Disease, 2015, 47, 939-954.	2.6	63
240	Neuropsychiatric symptoms in people screened positive for dementia in primary care. International Psychogeriatrics, 2015, 27, 39-48.	1.0	26
241	Subjective memory impairment: No suitable criteria for caseâ€finding ofÂdementia in primary care. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 179-186.	2.4	16
242	Dysexecutive functioning in ALS patients and its clinical implications. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 160-171.	1.7	30
243	P4-094: Predictors of cognitive response to cholinergic treatment in patients with Alzheimer's disease dementia. , 2015, 11, P809-P810.		0
244	IC-P-080: Analysis of intermodal associations and dependencies of regional disease patterns based on multimodal imaging using markov random fields. , 2015, 11, P58-P58.		0
245	IC-P-105: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: AÂmulticenter DTI and volumetry study. , 2015, 11, P72-P72.		0
246	P3-179: A comparison of hippocampal volume and integrity: Which is the better predictor of cognitive decline?. , 2015, 11, P698-P699.		0
247	P4-044: Feasibility of a cognitive rehabilitation group program for patients with mild dementia in Alzheimer's disease: A randomized, controlled, single-blinded pilot study. , 2015, 11, P783-P783.		0
248	P4-133: Depressive symptoms and depression in people screened positive for dementia. , 2015, 11, P829-P829.		0
249	O2-08-01: Diagnosis of dementia in primary care: The effect of screening. , 2015, 11, P191-P191.		1
250	O2-10-03: In vivo characterization of basal forebrain atrophy and cholinergic denervation in primary progressive aphasia. , 2015, 11, P198-P198.		0
251	Multimodal analysis of functional and structural disconnection in <scp>A</scp> lzheimer's disease using multiple kernel <scp>SVM</scp> . Human Brain Mapping, 2015, 36, 2118-2131.	3.6	156
252	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusionâ€Tensor and Magnetic Resonance Imaging Data. Journal of Neuroimaging, 2015, 25, 738-747.	2.0	79

#	Article	IF	CITATIONS
253	A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. Neuropsychologia, 2015, 69, 1-8.	1.6	25
254	Cholinergic Basal Forebrain Structure Influences the Reconfiguration of White Matter Connections to Support Residual Memory in Mild Cognitive Impairment. Journal of Neuroscience, 2015, 35, 739-747.	3.6	45
255	Training labels for hippocampal segmentation based on the EADCâ€ADNI harmonized hippocampal protocol. Alzheimer's and Dementia, 2015, 11, 175-183.	0.8	105
256	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.8	162
257	The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment — Beyond classical regression. NeuroImage: Clinical, 2015, 8, 583-593.	2.7	77
258	Association of a neurokinin 3 receptor polymorphism with the anterior basal forebrain. Neurobiology of Aging, 2015, 36, 2060-2067.	3.1	9
259	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. Alzheimer's Research and Therapy, 2015, 7, 27.	6.2	13
260	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.8	152
261	The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 81-86.	2.4	7
262	Hippocampus and basal forebrain volumes modulate effects ofÂanticholinergic treatment on delayed recall in healthy older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 216-219.	2.4	4
263	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurology, The, 2015, 14, 1037-1053.	10.2	233
264	Microstructural White Matter Changes Underlying Cognitive and Behavioural Impairment in ALS – An In Vivo Study Using DTI. PLoS ONE, 2014, 9, e114543.	2.5	54
265	Antipsychotic Drug Treatment in Ambulatory Dementia Care: Prevalence and Correlates. Journal of Alzheimer's Disease, 2014, 43, 1303-1311.	2.6	12
266	Decline of fiber tract integrity over the adult age range: A diffusion spectrum imaging study. Journal of Magnetic Resonance Imaging, 2014, 40, 348-359.	3.4	9
267	Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin. Neurology, 2014, 83, 1930-1935.	1.1	107
268	Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1973-1981.	3.1	52
269	Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala's nucleus. Psychiatry Research - Neuroimaging, 2014, 221, 187-194.	1.8	25
270	Diffusion tensor imaging in Alzheimer's disease and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 467-483.	3.2	24

#	Article	IF	CITATIONS
271	The ε4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 401-404.	0.8	25
272	Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. Journal of Alzheimer's Disease, 2014, 40, 687-700.	2.6	173
273	CSF Al 2 1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392.		64
274	Standardization of MRI and Amyloid Imaging. , 2014, , 131-156.		2
275	Functional and Structural MRI in Alzheimer's Disease: A Multimodal Approach. , 2014, , 371-422.		0
276	Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia. Journal of Neurology, 2014, 261, 1939-1948.	3.6	113
277	Fractional Anisotropy Changes in Alzheimer's Disease Depend on the Underlying Fiber Tract Architecture: A Multiparametric DTI Study using Joint Independent Component Analysis. Journal of Alzheimer's Disease, 2014, 41, 69-83.	2.6	71
278	Cortical thinning and its relation to cognition in amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 240-246.	3.1	72
279	Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimer's and Dementia, 2014, 10, S344-53.	0.8	79
280	Genetic interaction of <i>PICALM</i> and <i>APOE</i> is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S269-76.	0.8	47
281	Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 482-491.	3.1	94
282	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	4.4	105
283	Rates of Formal Diagnosis in People Screened Positive for Dementia in Primary Care: Results of the DelpHi-Trial. Journal of Alzheimer's Disease, 2014, 42, 451-458.	2.6	88
284	P3-185: THE EUROPEAN DTI STUDY IN DEMENTIA: A NOVEL FRAMEWORK TO TEST THE DIAGNOSTIC USE OF DTI IN ALZHEIMER'S DISEASE. , 2014, 10, P697-P697.		1
285	IC-P-180: STRUCTURAL CONNECTIVITY CHANGES UNDERLYING ALTERED WORKING MEMORY NETWORKS IN MILD COGNITIVE IMPAIRMENT: A THREE-WAY IMAGE FUSION ANALYSIS. , 2014, 10, P101-P101.		1
286	IN VIVO IMAGING OF BASAL FOREBRAIN ATROPHY: A POTENTIAL IMAGING MARKER OF PREDEMENTIA ALZHEIMER'S DISEASE. , 2014, 10, P213-P213.		0
287	Molecular imaging of dementia. Geriatric Mental Health Care, 2013, 1, 56-62.	0.3	4
288	Detecting the Effect of Alzheimer's Disease on Everyday Motion Behavior. Journal of Alzheimer's Disease, 2013, 38, 121-132.	2.6	47

#	Article	IF	CITATIONS
289	Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15097-15102.	7.1	50
290	Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1210-1220.	3.1	169
291	Cognitive assistance to support social integration in Alzheimer's disease. Geriatric Mental Health Care, 2013, 1, 39-45.	0.3	12
292	Risk and resilience: A new perspective on Alzheimer's disease. Geriatric Mental Health Care, 2013, 1, 47-55.	0.3	4
293	Relevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 399-424.	2.5	151
294	Long-Term Test-Retest Reliability of Resting-State Networks in Healthy Elderly Subjects and Patients with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2013, 34, 741-754.	2.6	46
295	Robust Automated Detection of Microstructural White Matter Degeneration in Alzheimer's Disease Using Machine Learning Classification of Multicenter DTI Data. PLoS ONE, 2013, 8, e64925.	2.5	89
296	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. Advances in Biological Psychiatry, 2012, , 80-114.	0.2	0
297	Anatomical MRI and DTI in the Diagnosis of Alzheimer's Disease: A European Multicenter Study. Journal of Alzheimer's Disease, 2012, 31, S33-S47.	2.6	86
298	Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials, 2012, 13, 56.	1.6	92
299	Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease. Biological Psychiatry, 2012, 71, 805-813.	1.3	254
300	Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S329-S347.	2.6	21
301	Automated tractography of the cingulate bundle in Alzheimer's disease: A multicenter DTI study. Journal of Magnetic Resonance Imaging, 2012, 36, 84-91.	3.4	33
302	Isolated motor neglect following infarction of the posterior limb of the right internal capsule: a case study with diffusion tensor imaging-based tractography. Journal of Neurology, 2012, 259, 100-105.	3.6	8
303	Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. Biological Psychiatry, 2011, 70, 145-151.	1.3	24
304	Increased CSF-BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 373-381.	2.6	50
305	Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Progress in Neurobiology, 2011, 95, 547-556.	5.7	30
306	Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. Progress in Neurobiology, 2011, 95, 570-578.	5.7	22

#	Article	IF	CITATIONS
307	Staging Alzheimer's disease progression with multimodality neuroimaging. Progress in Neurobiology, 2011, 95, 535-546.	5.7	68
308	The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology, 2011, 95, 718-728.	5.7	190
309	Automated Detection of Amyloid-Î ² -Related Cortical and Subcortical Signal Changes in a Transgenic Model of Alzheimer's Disease using High-Field MRI. Journal of Alzheimer's Disease, 2011, 23, 221-237.	2.6	28
310	Effects of a Newly Developed Cognitive Intervention in Amnestic Mild Cognitive Impairment and mild Alzheimer's disease: A Pilot Study. Journal of Alzheimer's Disease, 2011, 25, 679-694.	2.6	121
311	Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiatry Research - Neuroimaging, 2011, 194, 363-371.	1.8	98
312	The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. Human Brain Mapping, 2011, 32, 1349-1362.	3.6	136
313	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. World Journal of Biological Psychiatry, 2011, 12, 109-113.	2.6	8
314	Test–retest reproducibility of the defaultâ€mode network in healthy individuals. Human Brain Mapping, 2010, 31, 237-246.	3.6	174
315	Longitudinal Changes in Fiber Tract Integrity in Healthy Aging and Mild Cognitive Impairment: A DTI Follow-Up Study. Journal of Alzheimer's Disease, 2010, 22, 507-522.	2.6	157
316	Diagnostic Utility of Novel MRI-Based Biomarkers for Alzheimer's Disease: Diffusion Tensor Imaging and Deformation-Based Morphometry. Journal of Alzheimer's Disease, 2010, 20, 477-490.	2.6	31
317	Altered Brain Activation During a Verbal Working Memory Task in Subjects with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 103-118.	2.6	86
318	Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2010, 182, 244-250.	1.8	46
319	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Reviews Drug Discovery, 2010, 9, 560-574.	46.4	560
320	Reduction of Basal Forebrain Cholinergic System Parallels Cognitive Impairment in Patients at High Risk of Developing Alzheimer's Disease. Cerebral Cortex, 2010, 20, 1685-1695.	2.9	183
321	Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. NeuroImage, 2010, 50, 162-174.	4.2	287
322	White matter microstructure underlying default mode network connectivity in the human brain. NeuroImage, 2010, 49, 2021-2032.	4.2	185
323	Regional networks underlying interhemispheric connectivity: An EEG and DTI study in healthy ageing and amnestic mild cognitive impairment. Human Brain Mapping, 2009, 30, 2098-2119.	3.6	85
324	Improved detection of incipient vascular changes by a biotechnological platform combining post mortem MRI in situ with neuropathology. Journal of the Neurological Sciences, 2009, 283, 2-8.	0.6	28

#	Article	IF	CITATIONS
325	White Matter Microstructure in Relation to Education in Aging and Alzheimer's Disease1. Journal of Alzheimer's Disease, 2009, 17, 571-583.	2.6	84
326	Assessment of factors that confound MRI and neuropathological correlation of human postmortem brain tissue. Cell and Tissue Banking, 2008, 9, 195-203.	1.1	37
327	Novel MRI techniques in the assessment of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 58-69.	6.4	79
328	Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiology of Aging, 2008, 29, 23-30.	3.1	242
329	Increased CSF-BACE 1 activity is associated with ApoE-Îμ4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain, 2008, 131, 1252-1258.	7.6	109
330	White Matter Damage in Alzheimer Disease and Mild Cognitive Impairment: Assessment with Diffusion-Tensor MR Imaging and Parallel Imaging Techniques. Radiology, 2007, 243, 483-492.	7.3	197
331	Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment. Archives of General Psychiatry, 2007, 64, 718.	12.3	196
332	Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. Brain, 2007, 130, 1745-1758.	7.6	47
333	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neurolmage, 2007, 34, 985-995.	4.2	162
334	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. NeuroImage, 2007, 38, 13-24.	4.2	185
335	Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 330-336.	3.2	28
336	Neuroanatomy of Down Syndrome in vivo: A Model of Preclinical Alzheimer's Disease. Behavior Genetics, 2006, 36, 405-415.	2.1	131
337	Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. Journal of Neurology, 2006, 253, 794-800.	3.6	106
338	Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology, 2006, 187, 86-94.	3.1	62
339	Response to Boban et al: computer-assisted 3D reconstruction of the nucleus basalis complex, including the nucleus subputaminalis (Ayala's nucleus). Brain, 2006, 129, E43-E43.	7.6	15
340	Focal Decline of Cortical Thickness in Alzheimer's Disease Identified by Computational Neuroanatomy. Cerebral Cortex, 2005, 15, 995-1001.	2.9	390
341	Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain, 2005, 128, 2626-2644.	7.6	213
342	Ageâ€related cortical grey matter reductions in nonâ€demented Down's syndrome adults determined by MRI with voxelâ€based morphometry. Brain, 2004, 127, 811-824.	7.6	135

#	Article	IF	CITATIONS
343	Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231. Archives of Neurology, 2002, 59, 1267.	4.5	256
344	Progression of Corpus Callosum Atrophy in Alzheimer Disease. Archives of Neurology, 2002, 59, 243.	4.5	167
345	Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. Journal of the Neurological Sciences, 2002, 194, 15-19.	0.6	47
346	Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Annals of Neurology, 2001, 49, 545-546.	5.3	99
347	Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Annals of Neurology, 2001, 49, 545-546.	5.3	1
348	Corpus Callosum Measurement as an <i>in Vivo</i> Indicator for Neocortical Neuronal Integrity, but not White Matter Pathology, in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 903, 470-476.	3.8	15
349	Corpus Callosum Atrophy Is a Possible Indicator of Region– and Cell Type–Specific Neuronal Degeneration in Alzheimer Disease. Archives of Neurology, 1998, 55, 193.	4.5	178